Overview

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Status:
Not yet recruiting

Trial end date:
2024-05-24

Target enrollment:

Participant gender:

Summary

The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembrolizumab. The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors (melanoma, colorectal cancer [CRC], hepatocellular carcinoma [HCC]) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab